Drug treatment has the potential to reduce incidence of blood-borne infections by helping injection drug users (1DUs) achieve abstinence or by decreasing the frequency of injection and sharing practices. We studied the associations between retention in methadone treatment and drug use behaviors and incidence of hepatitis B and C in a cohort of IDUs in the Seattle, Washington, area. Data on IDUs entering methadone treatment at four centers in King County, Washington, were collected through face-to-face interviews using a standardized questionnaire at baseline and 12-month follow-up between October 1994 and January 1998. Blood specimens were obtained and tested for human immunodeficiency virus (HIV) and hepatitis B and C. Drug treatment status at follow-up was analyzed in relation to study enrollment characteristics and potential treatment outcomes, including injection risk behaviors, cessation or reduced frequency of injection, and incidence of hepatitis B and C. Of 716 IDUs, 292 (41%) left treatment, 198 (28%) disrupted (left and returned) treatment, and 226 (32%) continued treatment throughout the 1-year follow-up period. Compared to those who left treatment, subjects who disrupted or continued were less likely to inject at follow-up (odds ratio [OR] = 0.5, 95% CI 0.3-0.7; and OR = 0.1, 95% CI 0.1-0.2, respectively). Among the 468 (65%) subjects who continued injecting, those who continued treatment injected less frequently, were less likely to pool money to buy drugs (OR = 0.5, 95% CI 0.3-0.8) and inject with used needles (OR = 0.5, 95% CI 0.2-0.8) compared to those who left treatment. Cooker or cotton sharing was not associated with retention in treatment, but hepatitis B incidence was lowest among those who continued treatment. The results of this study suggest drug use risk reduction is more likely to be achieved by those who remain in drug treatment and by those who stop injecting, but that those who drop out and return and those who continue to inject while in treatment Drs.
INTRODUCTION
Injection drug use continues to remain an important route of transmission for human immunodeficiency virus (HIV), accounting for almost one-third of all acquired immunodeficiency syndrome (AIDS) cases reported in the US and a rapidly rising number of infections in eastern Europe and Asia. 1"2 Des Jarlais et al., 3' 4 however, reported a substantial decrease in HIV incidence and prevalence among injection drug users (IDUs) in New York City in the 1990s, and several studies have noted declines in risky injection practices in the US and elsewhere that are thought to have resulted in lower HIV transmission rates among specific IDU populations, s-9 Hepatitis B (HBV) and hepatitis C (HCV) prevalence and incidence, on the other hand, continue to remain high among IDUs in many areas where HIV prevalence has remained low or has decreased, 5"1~ and residual injection and sexual risk behaviors suggest that work remains to be accomplished to control transmission of blood-borne viruses.
Drug treatment has been an important component of HIV prevention for many years, and methadone treatment has been associated with reduction in risky drug use and sexual behaviors, as well as lower HIV prevalence and incidence. [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] Less is understood about the effect of methadone treatment on HBV and HCV transmission, and two studies did not show reduced HCV incidence among methadone treatment participants. Selvey et al. 22 reported an HCV seroconversion rate of 11 per 100 person-years among methadone clients and no association between duration of methadone treatment and seroconversion. A study by Crofts et al. 23 found no differences in HCV seroconversion rates between Melbourne, Australia, IDUs in methadone maintenance treatment versus those not in treatment. This raises questions regarding the contribution of drug treatment to HBV and HCV control and to reductions in injection risk behaviors.
King County, Washington, is located on the Puget Sound in the northwestern part of the US. The population of 1.7 million includes those living in Seattle, the county's largest city. There are an estimated 10,000-15,000 IDUs in King County, most of whom are opiate users. During the time of this study, there were 1,750 methadone treatment slots in the county, most of which were occupied, and those on waiting lists for methadone treatment numbered in the hundreds. In this study, we examined the associations between retention in methadone treat-ment and drug use behaviors and incidence of HIV and hepatitis B and C infection.
METHODS

SUBJ[CTS AND DATA COLLECTION
Data on IDUs entering methadone treatment were collected as part of the RAVEN (Risk Activity Variables, Epidemiology, and Networks) Study, a longitudinal study of injectors recruited at in-and out-of-treatment settings in the Seattle-King County area. The drug treatment center component was part of a multisite study of risk behaviors and HIV prevalence and incidence; the study was funded by the Centers for Disease Control and Prevention. Eligibility criteria included injection of illicit drugs in the past 12 months, age 14 years or older, working knowledge of English or Spanish, and recent admission to the specific drug treatment facility. A random numbers scheme was used to select study participants from among IDUs entering treatment at all four methadone treatment facilities in King County between October 1994 and January 1997. Trained study interviewers administered a standardized questionnaire; provided counseling for prevention of HW, HBV and HCV infections, and other blood-borne and sexually transmitted diseases; and collected a blood sample at the baseline and 1-year follow-up visits. Participants were informed of their test results and offered referral to appropriate health and social services, including hepatitis B vaccination. The questionnaire included sociodemographic characteristics and drug use, sexual practice, and general health behaviors. The reference periods for the behavioral questions were I month prior to baseline and follow-up, 6 months prior to baseline, and the interval between baseline and follow-up. This analysis focused on behaviors at baseline and at follow-up and included behaviors in the month prior to those study visits. Participants were paid $10 for completing the baseline visit and $25 for completing the follow-up visit. An active follow-up program included contacting participants by mail or telephone 6 weeks, 3 months, and 6 months after the enrollment visit to update locator information and searching treatment and jail records and death certificate databases to find lost participants or identify deaths among study subjects.
LABORATORY TESTING
The Public Health--Seattle-King County Laboratory performed serological testing for this study. Sera were screened for anti-HIV using enzyme immunoassay (EIA, Abbott Laboratories; Abbott Park, IL), and positive results were confirmed using Western blot (Novopath HIV-1 Immunoblot, Bio-Rad; Hercules, CA). Test-ing for anti-HCV was by a third-generation enzyme immunoassay (EIA; Abbott Laboratories), and repeat testing was used to confirm positive results. For HBV, sera were tested first for anti-HBc (HBV core antibodies) using an EIA (corzyme) (Abbott Laboratories); all positive specimens were further tested for HBsAg (HBV surface antigen), also using an EIA (auszyme monoclonal) (Abbott Laboratories).
ANALYSIS
This analysis included subjects recruited at drug treatment agencies who had injected in the month before study enrollment and completed their 1-year followup visit. Drug treatment status at follow-up was ascertained by self-report at the follow-up interview; the date of admission was verified through review of drug treatment records. Treatment status was classified as follows: (1) Outcome variables included injection risk behaviors among those who injected at follow-up, including pooling of money with someone else to buy drugs, use of a drug cooker or filtration cotton after someone else, use of a syringe to divide drugs between two or more IDUs (backloading), and injecting with a needle previously used by someone else; cessation of injection and incidence of HCV and HBV were measured in all subjects. Univariate analyses using chi-square tests were conducted to assess associations between drug treatment status at follow-up and sociodemographic and drug use variables at baseline. Chi-square trends were calculated to determine whether there was an intermediate effect of disrupted treatment on outcomes in both univariate and multivariate analyses.
Associations between drug treatment status at follow-up and outcome variables were assessed in multivariate analysis using logistic regression to control for potential confounders. Potential confounders included race, age, incarceration in the 6 months before enrollment, the number of years since first injection, and frequency of weekly injections in the month before baseline, and, for HBV seroconversion, HBV vaccination status at baseline. Monthly income was not ascertained for the full study period and was not considered in the multivariate model because information on it was missing for a high proportion of participants.
With the exception of frequency of weekly injections in the model to assess injection cessation and the specific risk behavior at baseline in each of the risk behavior models, only factors that changed the odds ratio (OR) of interest by 10% or more were retained in the model. Behaviors referred to in the tables and text as "at baseline" or "at follow-up" are behaviors reported to have occurred in the month before that study visit.
RESULTS
SUBJECTS INCLUDKiD IN ANALYSIS
A total of 999 systematically selected persons who met initial eligibility criteria agreed to participate in the drug treatment arm of the study between October 1994 and January 1997. The participation rate was 83%, and the 1-year followup rate was 84%. After exclusion of data from the second enrollment visit of 4 subjects who entered the study twice, 24 who entered a nonmethadone treatment program at enrollment, 153 who did not complete follow-up, 29 who were in a nonmethadone treatment program at follow-up, and 73 who did not inject in the month before study enrollment, data from 716 subjects were available for this analysis.
BASELINE CHARACTERISTICS
Among the 716 study participants, 44% were enrolled in a 6-month methadone detoxification program, and 56% were enrolled in a methadone maintenance program. There were 41% (292) who left methadone treatment, 28% (198) disrupted treatment, and 32% (226) continued treatment through the 1-year followup period (Table I) . There was no difference in treatment status at follow-up by whether clients were enrolled in a methadone detoxification or methadone maintenance program at baseline, probably because clients who enter a 6-month methadone detoxification program in the Seattle area often become methadone maintenance clients. The study population was 51% male and 77% white, with a median age of 38 years. Almost half (46%) had some college education, the majority (73%) were unemployed, 55% reported a legal monthly income of $500 or less, one-third did not have a permanent residence, and 35% had been in jail in the past 6 months. Participants who were white, older, had a higher income, and had not been in jail recently were more likely to continue treatment compared to others. A high proportion of African-American (55%) and unemployed participants (46%) left treatment.
The majority of subjects (74%) started injecting 10 years or more before study enrollment and injected at least daily (59%). Polydrug use was common; in Individual categories may not sum to totals because of exclusion of subjects with missing values. ns = not significant at P < .05.
addition to heroin injection, 42% also reported injecting heroin and cocaine together (speedballs), and 23% reported injecting cocaine alone. Cocaine injection was not associated with treatment status at follow-up (data not shown). Twothirds reported pooling of money with other injectors to buy drugs. Over half had used cookers or filtration cottons after someone else, one-third had shared a syringe to divide drugs 09ackloading), and one-third reported injecting with used needles. Study subjects who had injected for more than 10 years were more likely to continue treatment versus those who had injected fewer than 10 years.
HW prevalence was 1%, and HBV and HCV prevalence was 67% and 89%,
respectively. There were 14% who reported prior HBV vaccination.
UNIVARIATE ANALYSIS OF I;:tE[HAVIORS AND SEROLOGIE8 AT BASELINE AND FOLI OW-UP
A total of 468 study participants (65%) reported injecting at follow-up. There was a marked difference in reducing or stopping injection between the treatment status groups. Injecting in the last month was reported by 83% of those who left treatment, 70% of those who disrupted treatment, and 40% of those who continued treatment (Table II ) (P trend < .01). Among those who left treatment, the mean number of weekly injections was unchanged between baseline and followup (mean = 17) (Figure) . In contrast, among those who had disrupted treatment, the average weekly injections decreased by 56% (from 18 to 8), and among those who continued treatment, injections decreased by 80% (from 17 to 3) (P < .01).
Baseline injection risk behaviors were not related to treatment status at followup (Table I) ; for instance, subjects who reported injection with a syringe used by another injector were not more or less likely to remain in treatment than those who did not share syringes. As shown in Table II , treatment status at follow-up was associated with certain injection behaviors at follow-up among subjects who continued to inject. Fewer of those who continued treatment reported pooling of money to buy drugs (46%) and injection with used needles (24%) compared to those who left treatment (63% and 35%, respectively). Backloading was also less common among those who continued treatment (28%) versus those who left treatment (36%). Use of cookers or cottons after someone else, however, did not differ by treatment status.
Considering the low HIV prevalence in this study population, it was not surprising that no new HIV infections were observed during the 1-year followup period. Incidence of HBV was 6% and HCV was 9%. All 7 HCV seroconverters and 13 of the 14 HBV seroconverters reported injecting during follow-up. There was a significant trend toward lower HBV incidence by treatment status (P < .05) (Table II) . Among those who left treatment, HBV incidence was 11% compared to 4% in those who disrupted treatment and 3% in those who remained in treatment.
Only 13% of participants without serological markers of hepatitis B infection at baseline reported previous HBV vaccination, and only 13 additional subjects reported receiving vaccination during the follow-up period. There was also a Individual categories may not sum to totals because of exclusion of subjects with missing values.
*Adjusted for number of weekly injections at baseline.
-tAdjusted for the same behavior at baseline. :~P = .048 before rounding.
decreasing (not significant) downward trend for HCV seroconversion, with 12% incidence in those who left treatment, 10% in those who disrupted treatment, and 5% in those who continued treatment. Table II Cooker or cotton use at follow-up did not vary by treatment status. Both HBV and HCV incidence were lower among those in treatment at follow-up compared those who had left treatment, but only the difference in HBV infection approached statistical significance after adjusting for other factors.
MULTIVARIATE ANALYSIS OF OUTCOMES
F|GUR~ Mean number of estimated weekly injections at baseline and 1-year follow-up (n = 468) (BL = baseline; FU = follow-up).
D I S C U S S I O N
We found that drug injection and HIV risk behavior was less likely to occur among study participants who continued or disrupted but re-entered methadone treatment during the 1-year follow-up period. These lower risk behaviors included less frequent injection, cessation of injection, injection with used needles, and buying drugs with other IDUs. Furthermore, the proportion of subjects who stopped injecting and buying drugs with other injectors was highest among those who remained in treatment and lowest among those who left treatment. Among subjects who continued to inject, the greatest reduction in frequency of injections was observed among those who remained in treatment and was the least among those who left treatment. Lower HBV and HCV incidence was observed among those in treatment at follow-up, although the statistically significant trend toward lower incidence of HBV infection was only marginally significant after adjusting for confounders. and referrals to needle-exchange or outreach programs that do not stigmatize participants must be developed. These efforts must also include a much stronger emphasis on avoidance of cooker and cotton sharing and backloading.
Second, in spite of the availability of hepatitis B vaccine since 1982, selfreported vaccination rates among our study population, as well as other IDU populations, 29 were very low. While the majority of our study population had acquired immunity through infection by the time they entered drug treatment, about 30% remained susceptible, and seroconversions continued to occur during the follow-up period. Hardly any of our study participants accepted referral to a free vaccination, even though we were able to promise a shorter waiting time in the clinic, and transportation was free. Since drug treatment programs have repeated contact with clients over several months, hepatitis B vaccination ought to be incorporated routinely into these programs. This opportunity has not been utilized fully, perhaps because recommending vaccination suggests ongoing risk behavior or resuming risk behavior at some future date.
In summary, the results of this study emphasize the importance of (1) retaining opiate-dependent injectors in methadone treatment; (2) developing strategies to improve enrollment of recent-onset opiate injectors in methadone treatment to help them achieve long-term cessation of drug injection before they acquire Health--Seattle-King County Laboratory. We would also like to acknowledge the contribution of the late Dr. Noreen Harris, who initiated this study.
